Mylan (MYL) Suit Against FDA Over Hear Drug Dismissed - Bloomberg
Tweet Send to a FriendGet Alerts MYL Hot Sheet
Down)
Trade MYL Now!
Mylan, Inc. (NASDAQ: MYL) saw a little volume move higher following headlines that its suit against the FDA over a generic heart drug was dismissed, according to Bloomberg headlines.
Shares are down 1.4 percent on the session, but off of lows.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Shares are down 1.4 percent on the session, but off of lows.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Intuitive Surgical (ISRG) Jury Reaches Positive Verdict in Robot Case; Shares Rise
- Mylan (MYL) Launches Generic Tricor Tabs (ABBV)
- Salix Pharma (SLXP) Reports Positive Results From Two Budesonide Foam Phase 3s
Create E-mail Alert Related Categories
FDA, Litigation
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
